Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10622349 | 1.00 | GAA (0.59) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL13553151 | 0.94 | GAA (0.54) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL15501194 | 0.94 | GAA (0.54) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL20267325 | 0.94 | GAA (0.54) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL24070950 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL212672 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL9158281 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL447308 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL21202086 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL23541412 | 0.92 | GAA (0.56) | GAALGALS8LGALS3LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995005182-A1 | BRIDGED OLIGOSACCHARIDES AND SULFATED DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1995-02-23 | — | — | WO | claimed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-1995005182-A1 | BRIDGED OLIGOSACCHARIDES AND SULFATED DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | GAA 194/4885LGALS8 164/4885LGALS3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.